GeoVax Labs (GOVX) 10-Q 12 Nov 13 2013 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 12, 2013
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'GeoVax Labs, Inc.	'
Document Type	'10-Q	'
Current Fiscal Year End Date	'--12-31	'
Entity Common Stock, Shares Outstanding	'	21,716,610
Amendment Flag	'false	'
Entity Central Index Key	'0000832489	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Well-known Seasoned Issuer	'No	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$1,720,616	$1,035,925
Grant funds receivable	25,014	266,248
Prepaid expenses and other current assets	48,262	42,301
Total current assets	1,793,892	1,344,474
Property and equipment, net of accumulated depreciation and amortization of $474,956 and $429,804 at September 30, 2013 and December 31, 2012, respectively	143,936	102,486
Other assets:	'	'
Licenses, net of accumulated amortization of $236,355 and $228,856 at September 30, 2013 and December 31, 2012, respectively	12,500	20,000
Deposits and other assets	11,010	11,010
Total other assets	23,510	31,010
Total assets	1,961,338	1,477,970
Current liabilities:	'	'
Accounts payable	85,291	163,788
Accrued expenses	120,014	33,877
Amounts payable to Emory University (a related party)	20,225	129,370
Total current liabilities	225,530	327,035
Commitments (Note 4)	'	'
Stockholders’ equity:	'	'
Preferred stock, $0.01 par value, 10,000,000 shares authorized; Series A Convertible Preferred Stock, $1,000 stated value; 788 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively	312,196	312,196
Common stock, $0.001 par value, 75,000,000 shares authorized; 21,666,610 and 18,733,277 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively	21,667	18,733
Additional paid-in capital	27,582,316	25,587,148
Deficit accumulated during the development stage	-26,180,371	-24,767,142
Total stockholders’ equity	1,735,808	1,150,935
Total liabilities and stockholders’ equity	$1,961,338	$1,477,970

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Property and equipment, accumulated depreciation and amortization (in Dollars)	$474,956	$429,804
Licenses, accumulated amortization (in Dollars)	$236,355	$228,856
Preferred stock, par value (in Dollars per share)	$0.01	$0.01
Preferred stock, shares authorized (in Shares)	10,000,000	10,000,000
Common stock, par value (in Dollars per share)	$0.00	$0.00
Common stock, shares authorized (in Shares)	75,000,000	75,000,000
Common stock, shares issued (in Shares)	21,666,610	18,733,277
Common stock, shares outstanding (in Shares)	21,666,610	18,733,277
Series A Convertible Preferred Stock [Member]	'	'
Preferred stock, stated value (in Dollars per share)	$1,000	$1,000
Preferred stock, shares issued (in Shares)	788	788
Preferred stock, shares outstanding (in Shares)	788	788

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended		147 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Grant revenue	$1,004,211	$638,000	$2,242,812	$2,197,761	$25,211,831
Operating expenses:	'	'	'	'	'
Research and development	879,104	601,690	2,314,291	2,386,460	30,988,489
General and administrative	316,452	334,166	1,345,179	1,339,300	20,745,603
Total operating expenses	1,195,556	935,856	3,659,470	3,725,760	51,734,092
Loss from operations	-191,345	-297,856	-1,416,658	-1,527,999	-26,522,261
Other income (expense):	'	'	'	'	'
Interest income	1,197	1,077	3,429	2,944	347,559
Interest expense	'	'	'	'	-5,669
Total other income (expense)	1,197	1,077	3,429	2,944	341,890
Net loss	($190,148)	($296,779)	($1,413,229)	($1,525,055)	($26,180,371)
Basic and diluted:	'	'	'	'	'
Loss per common share (in Dollars per share)	($0.01)	($0.02)	($0.07)	($0.09)	($2.18)
Weighted average shares outstanding (in Shares)	21,666,610	18,497,886	20,979,675	17,400,665	12,026,183

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended		147 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Cash flows from operating activities:	'	'	'
Net loss	($1,413,229)	($1,525,055)	($26,180,371)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Depreciation and amortization	52,652	70,232	711,932
Accretion of preferred stock redemption value	'	'	346,673
Stock-based compensation expense	116,600	247,318	6,634,289
Investor warrant modification expense	238,169	'	390,295
Changes in assets and liabilities:	'	'	'
Grant funds receivable	241,234	-65,020	-25,014
Prepaid expenses and other current assets	-5,961	-17,204	-48,262
Deposits and other assets	'	'	-11,010
Accounts payable and accrued expenses	-101,505	-603,624	314,320
Total adjustments	541,189	-368,298	8,313,223
Net cash used in operating activities	-872,040	-1,893,353	-17,867,148
Cash flows from investing activities:	'	'	'
Purchase of property and equipment	-86,602	'	-625,092
Proceeds from sale of property and equipment	'	'	5,580
Net cash used in investing activities	-86,602	'	-619,512
Cash flows from financing activities:	'	'	'
Net proceeds from sale of common stock	1,643,333	310,160	17,479,801
Net proceeds from sale of preferred stock	'	1,999,032	2,727,475
Net cash provided by financing activities	1,643,333	2,309,192	20,207,276
Net increase in cash and cash equivalents	684,691	415,839	1,720,616
Cash and cash equivalents at beginning of period	1,035,925	1,167,980	'
Cash and cash equivalents at end of period	1,720,616	1,583,819	1,720,616
Supplemental disclosure of cash flow information:	'	'	'
Interest paid	'	'	$5,669

Note_1_Description_of_Company_

Note 1 - Description of Company and Basis of Presentation	9 Months Ended
	Sep. 30, 2013
Disclosure Text Block [Abstract]	'
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	'
	1.            Description of Company and Basis of Presentation
	GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a biotechnology company developing vaccines for the prevention and treatment of Human Immunodeficiency Virus (“HIV”) infections. HIV infections result in Acquired Immunodeficiency Syndrome (“AIDS”). We have exclusively licensed from Emory University (“Emory”) vaccine technology which was developed in collaboration with the National Institutes of Health (“NIH”) and the Centers for Disease Control and Prevention (“CDC”). GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in Smyrna, Georgia (metropolitan Atlanta area).
	Our most advanced vaccines under development address the clade B subtype of the HIV virus that is most prevalent in the United States and the developed world. Our vaccines are being evaluated to determine their potential to (a) prevent HIV infection and (b) to serve as a therapy for individuals who are already infected with HIV. These vaccines are currently being evaluated in human clinical trials.
	GeoVax is devoting all of its present efforts to research and development and is a development stage enterprise as defined by Financial Accounting Standards Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 915, “Development Stage Entities”. We have funded our activities to date almost exclusively from equity financings and government grants, and we will continue to require substantial funds to continue these activities. We anticipate that our existing cash resources, combined with the proceeds from the NIH grants discussed in Note 7, will be sufficient to fund our planned activities into the second quarter of 2014. In order to meet our future operating cash flow requirements, we intend to conduct additional offerings of our equity securities, debt or convertible debt instruments. We are also seeking additional funding for our vaccine development programs through government grants and clinical trial support.
	The accompanying financial statements at September 30, 2013 and for the three and nine month periods ended September 30, 2013 and 2012 are unaudited, but include all adjustments, consisting of normal recurring entries, which we believe to be necessary for a fair presentation of the dates and periods presented. Interim results are not necessarily indicative of results for a full year. The financial statements should be read in conjunction with our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2012. We expect our operating results to fluctuate for the foreseeable future; therefore, period-to-period comparisons should not be relied upon as predictive of the results in future periods.
	We disclosed in Note 2 to our financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2012 those accounting policies that we consider significant in determining our results of operations and financial position. There have been no material changes to, or in the application of, the accounting policies previously identified and described in the Form 10-K.

Note_2_Recent_Accounting_Prono

Note 2 - Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2013
Disclosure Text Block [Abstract]	'
Description of New Accounting Pronouncements Not yet Adopted [Text Block]	'
	2.            Recent Accounting Pronouncements
	There have been no recent accounting pronouncements or changes in accounting pronouncements during the nine months ended September 30, 2013, as compared to the recent accounting pronouncements described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2012, which we expect to have a material impact on our financial statements.

Note_3_Basic_and_Diluted_Loss_

Note 3 - Basic and Diluted Loss Per Common Share	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	3.            Basic and Diluted Loss Per Common Share
	Basic net loss per share is computed using the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares and potentially dilutive common share equivalents outstanding during the period. Potentially dilutive common share equivalents consist of convertible preferred stock, stock options and stock purchase warrants. Common share equivalents which potentially could dilute basic earnings per share in the future, and which were excluded from the computation of diluted loss per share, as the effect would be anti-dilutive, totaled approximately 10.3 million and 13.2 million shares at September 30, 2013 and 2012, respectively.

Note_4_Commitments

Note 4 - Commitments	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	4.            Commitments
	Lease Agreement
	We lease approximately 8,400 square feet of office and laboratory space located in Smyrna, Georgia (metropolitan Atlanta). As of September 30, 2013, our future minimum lease payments pursuant to the 62 month operating lease total $31,760 for the remainder of 2013 and $128,920 in 2014.
	Other Commitments
	In the normal course of business, we may enter into various firm purchase commitments related to production and testing of our vaccine material, conduct of our clinical trials, and other research-related activities. As of September 30, 2013, we had approximately $59,985 of unrecorded outstanding purchase commitments to our vendors and subcontractors, all of which we expect will be due in 2013.

Note_5_Stockholders_Equity

Note 5 - Stockholders' Equity	9 Months Ended
	Sep. 30, 2013
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	5.            Stockholders’ Equity
	Increase in Authorized Shares of Common Stock
	At our annual meeting of stockholders held on June 10, 2013, our stockholders approved an amendment to our certificate of incorporation to increase our authorized shares of common stock from 40,000,000 shares to 75,000,000 shares. The amendment to our certificate of incorporation was filed with the Delaware Secretary of State on August 1, 2013. In addition to the 21,666,610 shares of common stock outstanding at September 30, 2013, we have reserved the following shares of our common stock for future issuance:
	Common Stock Purchase Warrants		8,292,226
	Equity Incentive Plans		1,197,529
	Series A Convertible Preferred Stock		1,050,667
	Total		10,540,422
	Common Stock Transactions
	During January and May 2013, we issued an aggregate of 1,766,667 shares and 1,166,666 shares, respectively, of our common stock pursuant to the exercise of Series B Warrants, resulting in total proceeds of $1,060,000 and $583,333, respectively (see ”Stock Purchase Warrants” below).
	Stock Options
	The Company maintains a stock option plan that provides the Board of Directors broad discretion in creating equity incentives for employees, officers, directors and consultants. The following table presents a summary of stock option transactions during the nine months ended September 30, 2013:
		Number of Shares			Weighted Average
					Exercise Price
	Outstanding at December 31, 2012		1,069,141		$	4.5
	Granted		--			--
	Exercised		--			--
	Forfeited or expired		(78,429	)		4.86
	Outstanding at September 30, 2013		990,712		$	4.47
	Exercisable at September 30, 2013		679,036		$	6.14
	During the three month and nine month periods ended September 30, 2013, we recorded share-based compensation expense related to stock options of $33,348 and $116,600, as compared to $84,742 and $247,318 for the three month and nine month periods ended September 30, 2012, respectively. Share-based compensation expense is recognized on a straight-line basis over the requisite service period for the award and is allocated to research and development expense or general and administrative expense based upon the related employee classification. As of September 30, 2013, there was $135,418 of unrecognized compensation expense related to stock options, which is expected to be recognized over a weighted average period of 1.7 years.
	Stock Purchase Warrants
	We have issued stock purchase warrants in connection with financing transactions and also in exchange for services from consultants and others. The following table presents a summary of stock purchase warrant transactions during the nine months ended September 30, 2013:
		Number of Shares			Weighted Average
					Exercise Price
	Outstanding at December 31, 2012		11,225,559		$	2.06
	Issued		--			--
	Exercised		(2,933,333	)		0.56
	Forfeited or expired		--			--
	Outstanding at September 30, 2013		8,292,226		$	2.53
	Exercisable at September 30, 2013		8,292,226		$	2.53
	Effective January 17, 2013, we reduced the exercise price of our then-outstanding Series B Common Stock Purchase Warrants from $0.75 to $0.60 per share. In consideration for the reduction of the exercise price, the holders of the Series B Warrants immediately exercised 1,766,667 of the Series B Warrants for cash, resulting in total proceeds to the Company of $1,060,000. We also extended the expiration date of the unexercised Series B Warrants (1,166,667 shares in the aggregate) from March 21, 2013 to May 21, 2013. We recorded general and administrative expense of $218,551 associated with these warrant modifications, all of which was recognized during the three month period ended March 31, 2013.
	Effective May 14, 2013, we reduced the exercise price of the remaining Series B Common Stock Purchase Warrants from $0.60 to $0.50 per share. In consideration for the reduction of the exercise price, the holders of the Series B Warrants immediately exercised all 1,166,666 of the remaining Series B Warrants for cash, resulting in total proceeds to the Company of $583,333. We recorded general and administrative expense of $19,617 associated with this warrant modification, all of which was recognized during the three month period ended June 30, 2013.

Note_6_Income_Taxes

Note 6 - Income Taxes	9 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	6.            Income Taxes
	Because of our historically significant net operating losses, we have not paid income taxes since inception. We maintain deferred tax assets that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. These deferred tax assets are comprised primarily of net operating loss carryforwards and also include amounts relating to nonqualified stock options and research and development credits. The net deferred tax asset has been fully offset by a valuation allowance because of the uncertainty of our future profitability and our ability to utilize the deferred tax assets. Utilization of operating losses and credits may be subject to substantial annual limitations due to ownership change provisions of Section 382 of the Internal Revenue Code. The annual limitation may result in the expiration of net operating losses and credits before utilization.

Note_7_NIH_Grant_Funding

Note 7 - NIH Grant Funding	9 Months Ended
	Sep. 30, 2013
Grant Funding [Abstract]	'
Grant Funding [Text Block]	'
	7.            NIH Grant Funding
	In September 2007, the NIH awarded us an Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) grant to support our HIV/AIDS vaccine program. We are utilizing this funding to further our HIV/AIDS vaccine development, optimization and production. The aggregate award (including subsequent amendments) totaled $20.4 million, and there is approximately $773,000 remaining and available for use as of September 30, 2013.
	In September 2012, the NIH awarded us an additional grant of $1.9 million to support development of versions of our HIV/AIDS vaccines to address the clade C subtype of the HIV virus prevalent in the developing world. All funding pursuant to this grant has been utilized as of September 30, 2013.
	In July 2013, the NIH awarded us a Small Business Innovative Research (SBIR) grant entitled “Enhancing Protective Antibody Responses for a GM-CSF Adjuvanted HIV Vaccine.” The grant award of approximately $277,000 is for the first year of a two year project period beginning August 1, 2013, and there is approximately $249,000 remaining and available for use as of September 30, 2013.
	We record revenue associated with these grants as the related costs and expenses are incurred and such revenue is reported as a separate line item in our statements of operations.

Note_8_Related_Party_Transacti

Note 8 - Related Party Transactions	9 Months Ended
	Sep. 30, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	8.            Related Party Transactions
	We are obligated to reimburse Emory University (a significant stockholder of the Company) for certain prior and ongoing costs in connection with the filing, prosecution and maintenance of patent applications subject to our technology license agreement from Emory. During the nine month period ended September 30, 2013, we recorded $24,115 of general and administrative expense associated with these patent cost reimbursements to Emory.
	We have entered into a research agreement with Emory for the purpose of conducting research and development activities associated with our IPCAVD grant from the NIH (see Note 7). During the nine month period ended September 30, 2013, we recorded $252,478 of research and development expense associated with this contract. All amounts paid to Emory under this agreement are reimbursable to us pursuant to the NIH grant.

Note_5_Stockholders_Equity_Tab

Note 5 - Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2013
Stockholders' Equity Note [Abstract]	'
Common Stock Reserved for Future Issuance [Table Text Block]	'
	Common Stock Purchase Warrants		8,292,226
	Equity Incentive Plans		1,197,529
	Series A Convertible Preferred Stock		1,050,667
	Total		10,540,422
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
		Number of Shares			Weighted Average
					Exercise Price
	Outstanding at December 31, 2012		1,069,141		$	4.5
	Granted		--			--
	Exercised		--			--
	Forfeited or expired		(78,429	)		4.86
	Outstanding at September 30, 2013		990,712		$	4.47
	Exercisable at September 30, 2013		679,036		$	6.14
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'
		Number of Shares			Weighted Average
					Exercise Price
	Outstanding at December 31, 2012		11,225,559		$	2.06
	Issued		--			--
	Exercised		(2,933,333	)		0.56
	Forfeited or expired		--			--
	Outstanding at September 30, 2013		8,292,226		$	2.53
	Exercisable at September 30, 2013		8,292,226		$	2.53

Note_3_Basic_and_Diluted_Loss_1

Note 3 - Basic and Diluted Loss Per Common Share (Details)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Earnings Per Share [Abstract]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	10.3	13.2

Note_4_Commitments_Details

Note 4 - Commitments (Details) (USD $)	9 Months Ended
	Sep. 30, 2013
	sqft
Commitments and Contingencies Disclosure [Abstract]	'
Area of Real Estate Property (in Square Feet)	8,400
Operating Lease, Term of Lease	'62 months
Operating Leases, Future Minimum Payments, Remainder of Fiscal Year	$31,760
Operating Leases, Future Minimum Payments, Due in Two Years	128,920
Unrecorded Unconditional Purchase Obligation	$59,985

Note_5_Stockholders_Equity_Det

Note 5 - Stockholders' Equity (Details) (USD $)

1 Months Ended

3 Months Ended

9 Months Ended

147 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

1 Months Ended

31-May-13

Jan. 31, 2013

Jun. 30, 2013

Mar. 31, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Aug. 01, 2013

Jun. 10, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

14-May-13

Jan. 17, 2013

31-May-13

Jan. 31, 2013

13-May-13

Jan. 16, 2013

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Note 5 - Stockholders' Equity (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares Authorized (in Shares)

'

'

'

'

75,000,000

'

75,000,000

75,000,000

40,000,000

75,000,000

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares, Outstanding (in Shares)

'

'

'

'

21,666,610

'

21,666,610

'

'

18,733,277

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues (in Shares)

1,166,666

1,766,667

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Warrant Exercises

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$583,333

$1,060,000

$583,333

$1,060,000

'

'

Share-based Compensation

'

'

'

'

116,600

247,318

6,634,289

'

'

'

33,348

84,742

116,600

247,318

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized

'

'

'

'

'

'

'

'

'

'

135,418

'

135,418

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition

'

'

'

'

'

'

'

'

'

'

'

'

'1 year 255 days

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.5

0.6

'

'

0.6

0.75

(in Shares)

'

'

'

'

2,933,333

'

'

'

'

'

'

'

'

'

1,166,666

1,766,667

'

'

'

'

Class of Warrant or Right, Outstanding (in Shares)

'

'

'

'

8,292,226

'

8,292,226

'

'

11,225,559

'

'

'

'

'

1,166,667

'

'

'

'

Other General and Administrative Expense

'

'

$19,617

$218,551

$238,169

'

$390,295

'

'

'

'

'

'

'

'

'

'

'

'

'

Note_5_Stockholders_Equity_Det1

Note 5 - Stockholders' Equity (Details) - Common Stock Reserved for Future Issuance	Sep. 30, 2013
Note 5 - Stockholders' Equity (Details) - Common Stock Reserved for Future Issuance [Line Items]	'
Common Stock Reserved for Future Issuance	10,540,422
Common Stock Purchase Warrants [Member]	'
Note 5 - Stockholders' Equity (Details) - Common Stock Reserved for Future Issuance [Line Items]	'
Common Stock Reserved for Future Issuance	8,292,226
Equity Incentive Plans [Member]	'
Note 5 - Stockholders' Equity (Details) - Common Stock Reserved for Future Issuance [Line Items]	'
Common Stock Reserved for Future Issuance	1,197,529
Series A Convertible Preferred Stock [Member]	'
Note 5 - Stockholders' Equity (Details) - Common Stock Reserved for Future Issuance [Line Items]	'
Common Stock Reserved for Future Issuance	1,050,667

Note_5_Stockholders_Equity_Det2

Note 5 - Stockholders' Equity (Details) - Stock Option Transactions (USD $)	9 Months Ended
	Sep. 30, 2013
Stock Option Transactions [Abstract]	'
Outstanding at December 31, 2012	1,069,141
Outstanding at December 31, 2012 (in Dollars per share)	$4.50
Granted	0
Granted (in Dollars per share)	$0
Exercised	0
Exercised (in Dollars per share)	$0
Forfeited or expired	-78,429
Forfeited or expired (in Dollars per share)	$4.86
Outstanding at September 30, 2013	990,712
Outstanding at September 30, 2013 (in Dollars per share)	$4.47
Exercisable at September 30, 2013	679,036
Exercisable at September 30, 2013 (in Dollars per share)	$6.14

Note_5_Stockholders_Equity_Det3

Note 5 - Stockholders' Equity (Details) - Stock Purchase Warrant Transactions (USD $)	9 Months Ended
	Sep. 30, 2013
Stock Purchase Warrant Transactions [Abstract]	'
Outstanding at December 31, 2012 (in Shares)	11,225,559
Outstanding at December 31, 2012	$2.06
Issued (in Dollars)	$0
Issued	$0
Exercised (in Shares)	-2,933,333
Exercised	$0.56
Forfeited or expired (in Shares)	0
Forfeited or expired	$0
Outstanding at September 30, 2013 (in Shares)	8,292,226
Outstanding at September 30, 2013	$2.53
Exercisable at September 30, 2013 (in Shares)	8,292,226
Exercisable at September 30, 2013	$2.53

Note_7_NIH_Grant_Funding_Detai

Note 7 - NIH Grant Funding (Details) (USD $)	3 Months Ended		9 Months Ended		147 Months Ended	71 Months Ended		1 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Aug. 31, 2013	Sep. 30, 2013	Sep. 30, 2012	Jul. 31, 2013	Sep. 30, 2013
						First NIH Grant [Member]	First NIH Grant [Member]	Second NIH Grant [Member]	Third NIH Grant [Member]	Third NIH Grant [Member]
Note 7 - NIH Grant Funding (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'
Grant Award	'	'	'	'	'	$20,400,000	'	'	$277,000	'
Unused Grant Funds	'	'	'	'	'	'	773,000	'	'	249,000
Revenue from Grants	$1,004,211	$638,000	$2,242,812	$2,197,761	$25,211,831	'	'	$1,900,000	'	'
Project Period Covered by Grants	'	'	'	'	'	'	'	'	'2 years	'

Note_8_Related_Party_Transacti1

Note 8 - Related Party Transactions (Details) (USD $)	9 Months Ended
	Sep. 30, 2013
Ongoing Patent Cost Reimbursements [Member]	'
Note 8 - Related Party Transactions (Details) [Line Items]	'
Related Party Transaction, Expenses from Transactions with Related Party	$24,115
Research Agreements [Member]	'
Note 8 - Related Party Transactions (Details) [Line Items]	'
Related Party Transaction, Expenses from Transactions with Related Party	$252,478